GoldBamboo.com - Knowledge is strong medicine
  

Mechanisms of Skin Repair by Topical Estrogen - Article


  Not Signed In - Sign In / Register






Ethinyl Estradiol and Norgestrel

Cryselle; Lo/Ovral; Low-Ogestrel; Ogestrel; Ovral-28


Clinical Trial: Mechanisms of Skin Repair by Topical Estrogen

This study is currently recruiting patients.

Sponsors and Collaborators: University of Michigan
Pfizer
Information provided by: University of Michigan

Purpose

The purpose of this study is to investigate the way by which estrogen improves the appearance of sun damaged human skin. Accumulating evidence suggests that estrogen, taken by post menopausal women, may cause skin to look younger as a consequence of reduced wrinkles. Collagen is the most abundant protein in human skin and gives skin its strength and shape. Recent data indicate that short-term topical estrogen (17-beta estradiol) treatment increases collagen production in sun damaged skin. This study will compare the visual and microscopic effects from topical 17-beta estradiol (E2) when applied to the skin for a short-term duration. It is anticipated that the new knowledge from this study will enable development of new ways to improve the function of aged skin.

Condition Treatment or Intervention Phase
Skin Wrinkling
 Drug: Topical 17-beta estradiol in ethanol/propylene glycol (ETOH/PG)
Phase II

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Factorial Assignment, Pharmacokinetics/Dynamics Study

Official Title: Mechanisms of Skin Repair by Topical Estrogen in Vivo

Further Study Details: 
Primary Outcomes: Endpoints will include, protein and mRNA levels of collagen, elastin, hyaluronic acid, and other components of skin connective tissue
Secondary Outcomes: Appearance of aged or sun-damaged skin
Expected Total Enrollment:  200

Study start: August 2004;  Expected completion: December 2008
Last follow-up: August 2008;  Data entry closure: October 2008

The objectives of the study are to determine if topically-applied 17-beta estradiol (E2), alone or in combination with clobetasol, will produce clinical, histological and molecular effects distinguishable from vehicle in human skin. Specifically, the study will focus on regulation of collagen, elastin, and hyaluronic acid production and degradation in human skin, by steroid hormone receptors that are activated by estrogen or clobetasol. The sites to be treated will be buttock, hip, forearm, or facial skin. Subjects will receive between one to twelve vehicle (matching solution without any active ingredients), estrogen, and/or clobetasol topical treatments. Skin biopsies of treated areas will be obtained at baseline and at subsequent timepoints. The study will last up to two weeks. Endpoints will include protein and mRNA levels of collagen, elastin, hyaluronic acid, and other components of skin connective tissue. In addition, we will perform cDNA microanalysis to determine estrogen/clobetasol target genes in human skin. Secondary clinical endpoints related to the appearance of aging or sun damage may also be obtained. The results from our studies will provide new knowledge regarding the molecular basis of skin aging. This new knowledge will enable development of new ways to improve the function of aged skin.

Eligibility

Ages Eligible for Study:  50 Years and above,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

  • Healthy post-menopausal (without spontaneous menstrual bleeding for at least 1 year) women, and men, at least 50 years of age and any racial/ethnic type.
  • Subjects must understand and sign the informed consent prior to participation.
  • Subjects must be in generally good health.
  • Subjects must be available for follow-up visits to comply with the requirements of the protocol.
  • Not on estrogen replacement therapy within the past 3 months.
  • No nonsteroidal anti-inflammatory drugs two weeks prior to study entry.
  • No topical steroids two weeks prior to study entry.

Exclusion Criteria:

  • History of keloid formation or hypertrophic scarring.
  • History of reaction to lidocaine anesthetic.
  • Subjects with significant medical history or concurrent condition which the investigator(s) feel is not safe for study participation and which would impair evaluation of test sites.

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00113100


Michigan
      University of Michigan Department of Dermatology, Ann Arbor,  Michigan,  48109,  United States; Recruiting
Ted A Hamilton, MS  734-936-6394    tedah@umich.edu 
Gary J Fisher, PhD  734-763-1469    gjfisher@umich.edu 
Gary J Fisher, PhD,  Principal Investigator

More Information

Study ID Numbers:  Derm 530
Record last reviewed:  June 2005
Last Updated:  June 6, 2005
Record first received:  June 3, 2005
ClinicalTrials.gov Identifier:  NCT00113100
Health Authority: United States: Institutional Review Board (Awaiting confirmation)
ClinicalTrials.gov processed this record on 2005-06-07


Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Ethinyl Estradiol and Norgestrel.

October 10, 2008



Page Updated: June 1, 2005
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Massachusetts Law | Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.